Activity of 3'-hydroxychalcone against Cryptococcus gattii and toxicity, and efficacy in alternative animal models

This work aimed to evaluate the activity of 3'-hydroxychalcone against Cryptococcus gattii in planktonic and biofilm forms and their toxicity using alternative animal models. Minimum inhibitory concentration and minimum fungicide concentration were determined. Biofilm formation and the suscepti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Future microbiology 2017-10, Vol.12 (13), p.1123-1134
Hauptverfasser: Palanco, Ana Cerrejón, Lacorte Singulani, Junya de, Costa-Orlandi, Caroline Barcelos, Gullo, Fernanda Patrícia, Strohmayer Lourencetti, Natália Manuela, Gomes, Paulo César, Ayusso, Gabriela Miranda, Dutra, Luiz Antônio, Silva Bolzani, Vanderlan da, Regasini, Luis Octávio, Soares Mendes-Giannini, Maria José, Fusco-Almeida, Ana Marisa
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This work aimed to evaluate the activity of 3'-hydroxychalcone against Cryptococcus gattii in planktonic and biofilm forms and their toxicity using alternative animal models. Minimum inhibitory concentration and minimum fungicide concentration were determined. Biofilm formation and the susceptibility tests were performed by the 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-5-[carbonyl(phenylamino)]-2H-tetrazolium hydroxide assay. Toxicity and efficacy were checked in Danio rerio and Galleria mellonella models. The compound 3'-hydroxychalcone showed fungicidal activity against C. gattii in both planktonic and biofilm forms. The toxicity in zebrafish embryos revealed a low lethal concentration. In G. mellonella, the compound did not show antifungal activity and larvae toxicity. Because of the activity of 3'-hydroxychalcone against C. gattii in vitro, molecular modifications should be made to improve efficacy and to reduce toxicity in vivo. [Formula: see text].
ISSN:1746-0913
1746-0921
DOI:10.2217/fmb-2017-0062